V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20214850 | 20081079 | 1.72 | 103.3 | Palliative (P) | 2016-08-18 | 2016-09-01 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 101807029 |
| 20214851 | 20081080 | 1.75 | 80.4 | Palliative (P) | 2018-10-30 | 2018-11-10 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100459835 |
| 20214852 | 20081081 | 1.72 | 59 | Palliative (P) | 2016-11-10 | 2016-11-11 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101194972 |
| 20214853 | 20081082 | 1.85 | 55.2 | Palliative (P) | 2018-11-05 | 2018-11-20 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101144697 |
| 20214854 | 20081083 | 1.77 | 93.45 | Palliative (P) | 2018-01-20 | 2018-02-02 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101007072 |
| 20214856 | 20081084 | 1.71 | null | null | 2017-04-15 | 2017-04-27 | HCX (Cape + Cisp + Tras) - Load | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101252800 |
| 20214857 | 20081085 | 1.84 | 74.8 | Curative (C) | null | 2017-05-24 | TCX | 02 | null | FLUOROURACIL + MITOMYCIN + RT | 101468789 |
| 20214858 | 20081086 | 1.8 | 77 | Palliative (P) | 2017-02-07 | 2017-02-11 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100267544 |
| 20214859 | 20081087 | 1.79 | 109.2 | Curative (C) | null | 2018-04-10 | FLUOROURACIL + MITOMYCIN + RT | null | Y | FLUOROURACIL + MITOMYCIN + RT | 100718005 |
| 20214860 | 20081088 | null | 116.3 | Palliative (P) | 2018-06-22 | 2018-07-03 | LANREOTIDE | 02 | N | LANREOTIDE | 100483402 |
| 20214862 | 20081090 | 1.57 | 69.9 | null | 2018-02-08 | 2018-02-22 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | IMATINIB | 100004614 |
| 20214866 | 20081091 | 1.58 | 80.7 | Curative (C) | 2017-07-04 | 2017-07-21 | HCX | 02 | N | TRIAL | 100083458 |
| 20214868 | 20081092 | 1.76 | 71.8 | Curative (C) | 2018-06-15 | 2018-06-19 | FLUOROURACIL + MITOMYCIN + RT | 2 | Y | FLUOROURACIL + MITOMYCIN + RT | 101141735 |
| 20214869 | 20081093 | 1.62 | 88.8 | Palliative (P) | 2016-12-06 | 2016-12-31 | HCX (Cape + Cisp + Tras) - Load | 02 | N | TRIAL | 101475991 |
| 20214870 | 20081094 | 1.71 | 70.6 | Palliative (P) | 2017-10-03 | 2017-10-06 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100940441 |
| 20214871 | 20081095 | 1.69 | 95 | Palliative (P) | 2017-06-09 | 2017-06-16 | GO2 TRIAL | 1 | N | TRIAL | 100379676 |
| 20214872 | 20081096 | 1.63 | 71.4 | Neo-adjuvant (N) | 2017-10-25 | 2017-10-30 | Imatinib 400mg | N | N | IMATINIB | 100147040 |
| 20214873 | 20081097 | 1.59 | 117 | Palliative (P) | 2019-02-24 | 2019-03-23 | Cape+Cisplatin+Trastuzumab Load | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101745056 |
| 20214874 | 20081098 | 1.89 | 78.5 | 03 | 2017-11-06 | 2017-11-06 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101799618 |
| 20214875 | 20081099 | 1.72 | 110 | Curative (C) | null | 2018-11-13 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100896304 |
| 20214876 | 20081100 | 1.61 | 80.4 | Palliative (P) | 2017-02-26 | 2017-03-19 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100019592 |
| 20214879 | 20081102 | 1.62 | 82 | null | 2018-08-23 | 2018-08-23 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | LANREOTIDE | 101208517 |
| 20214880 | 20081103 | 1.65 | 78.3 | null | 2019-06-05 | 2019-06-26 | Cape+Cisplatin+Trastuzumab Main | 02 | null | IMATINIB | 100034780 |
| 20214881 | 20081104 | 1.5 | 81 | Curative (C) | 2016-10-03 | 2016-10-12 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | FLUOROURACIL + MITOMYCIN + RT | 100896970 |
| 20214882 | 20081105 | 1.67 | 104.4 | Curative (C) | null | 2018-01-23 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100490931 |
| 20214883 | 20081106 | null | 61.6 | Palliative (P) | 2016-08-25 | 2016-08-25 | LANREOTIDE | 02 | N | LANREOTIDE | 100950618 |
| 20214885 | 20081107 | null | null | Palliative (P) | 2021-10-02 | 2021-10-04 | LANREOTIDE | 02 | N | LANREOTIDE | 100516897 |
| 20214886 | 20081108 | 1.58 | 126 | Palliative (P) | 2017-04-22 | 2017-04-24 | IMATINIB | 02 | N | IMATINIB | 101026706 |
| 20214887 | 20081109 | 0 | 74 | null | 2018-12-23 | 2019-01-05 | Cape+Cisplatin+Trastuzumab Load | 02 | null | LANREOTIDE | 100602372 |
| 20214888 | 20081110 | 1.7 | 80.5 | Palliative (P) | null | 2014-05-11 | null | null | N | TRIAL | 100057384 |
| 20214889 | 20081111 | 1.77 | 86.5 | Neo-adjuvant (N) | 2016-10-12 | 2016-10-27 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101801574 |
| 20214891 | 20081113 | 1.67 | 70.6 | Palliative (P) | 2017-05-18 | 2017-05-18 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101751699 |
| 20214893 | 20081114 | 1.71 | 108.4 | null | 2016-05-01 | 2016-05-15 | HCX (Cape + Cisp + Tras) - Load | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100347945 |
| 20214894 | 20081115 | 1.6 | 58.3 | Palliative (P) | 2017-09-07 | 2017-09-16 | HCX (Cape + Cisp + Tras) - Main | 02 | N | TRIAL | 101488086 |
| 20214895 | 20081116 | 1.7 | 50 | Neo-adjuvant (N) | 2018-05-04 | 2018-05-05 | GO2 TRIAL | 01 | N | TRIAL | 101279291 |
| 20214896 | 20081117 | 1.72 | 69 | Palliative (P) | 2018-11-27 | 2018-11-27 | Trial Unspecified | Y | null | TRIAL | 100471720 |
| 20214898 | 20081119 | 1.6 | 77.5 | Curative (C) | 2018-12-21 | 2018-12-21 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100108905 |
| 20214899 | 20081120 | 1.73 | 61.1 | Palliative (P) | 2019-10-10 | 2019-10-10 | Trial Unspecified | N | N | TRIAL | 100355624 |
| 20214901 | 20081122 | 1.82 | 60.4 | Neo-adjuvant (N) | 2016-06-27 | 2016-07-18 | HCX (Cape + Cisp + Tras) - Load | 02 | N | IMATINIB | 100939900 |
| 20214902 | 20081123 | 1.75 | 62.1 | Palliative (P) | 2018-07-10 | 2018-07-31 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100778382 |
| 20214903 | 20081124 | 1.7 | 71.2 | Curative (C) | 2016-07-15 | 2016-08-19 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100196777 |
| 20214904 | 20081125 | 1.6 | 67.7 | Palliative (P) | 2019-07-05 | 2019-07-18 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100191591 |
| 20214906 | 20081126 | 1.5 | 0 | Curative (C) | 2016-04-27 | 2016-04-27 | Imatinib 400mg | 02 | N | IMATINIB | 100623417 |
| 20214907 | 20081127 | 1.79 | 63.1 | Disease modification (D) | 2018-08-11 | 2018-08-20 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | LANREOTIDE | 100571351 |
| 20214908 | 20081128 | 1.73 | 73.6 | Palliative (P) | 2017-02-03 | 2017-02-03 | SIEGE TRIAL | 1 | N | TRIAL | 101724259 |
| 20214909 | 20081129 | null | 68 | Curative (C) | 2018-01-09 | 2018-01-09 | Cape+Cisplatin+Trastuzumab Load | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100769305 |
| 20214910 | 20081130 | null | null | null | 2017-07-10 | 2017-10-22 | Cape+Cisplatin+Trastuzumab Load | 02 | Y | TRIAL | 100687275 |
| 20214911 | 20081131 | 1.56 | 82 | Palliative (P) | 2009-06-07 | 2018-08-01 | IMATINIB | 02 | N | IMATINIB | 100956177 |
| 20214912 | 20081132 | 1.85 | 80 | Curative (C) | 2017-03-26 | 2017-04-10 | Fluorouracil+Mitomycin+RT (Bladder) | N | N | FLUOROURACIL + MITOMYCIN + RT | 100294619 |
| 20214913 | 20081133 | null | 86.4 | Palliative (P) | 2017-03-06 | 2017-04-03 | LANREOTIDE | 02 | N | LANREOTIDE | 101133607 |